Future Fund LLC Purchases 11,017 Shares of Penumbra, Inc. $PEN

Future Fund LLC increased its stake in shares of Penumbra, Inc. (NYSE:PEN) by 177.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 17,221 shares of the company’s stock after acquiring an additional 11,017 shares during the quarter. Penumbra makes up about 1.9% of Future Fund LLC’s investment portfolio, making the stock its 4th largest position. Future Fund LLC’s holdings in Penumbra were worth $5,354,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC lifted its position in Penumbra by 27.1% during the fourth quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock worth $55,000 after buying an additional 38 shares in the last quarter. Swiss Life Asset Management Ltd lifted its position in Penumbra by 2.3% during the fourth quarter. Swiss Life Asset Management Ltd now owns 1,728 shares of the company’s stock worth $537,000 after buying an additional 39 shares in the last quarter. Abbot Financial Management Inc. lifted its position in Penumbra by 1.3% during the third quarter. Abbot Financial Management Inc. now owns 3,254 shares of the company’s stock worth $824,000 after buying an additional 42 shares in the last quarter. Glenview Trust Co lifted its position in Penumbra by 5.0% during the third quarter. Glenview Trust Co now owns 904 shares of the company’s stock worth $229,000 after buying an additional 43 shares in the last quarter. Finally, Keybank National Association OH lifted its position in Penumbra by 1.2% during the fourth quarter. Keybank National Association OH now owns 3,705 shares of the company’s stock worth $1,152,000 after buying an additional 43 shares in the last quarter. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Insiders Place Their Bets

In other Penumbra news, Director Harpreet Grewal sold 100 shares of Penumbra stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $328.22, for a total value of $32,822.00. Following the sale, the director owned 8,719 shares in the company, valued at $2,861,750.18. The trade was a 1.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Maggie Yuen sold 2,432 shares of Penumbra stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $342.30, for a total value of $832,473.60. Following the completion of the sale, the chief financial officer owned 18,353 shares in the company, valued at $6,282,231.90. This represents a 11.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.90% of the stock is owned by insiders.

Penumbra Price Performance

NYSE:PEN opened at $318.46 on Friday. Penumbra, Inc. has a 52 week low of $221.26 and a 52 week high of $362.41. The company has a quick ratio of 3.95, a current ratio of 6.02 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $12.53 billion, a P/E ratio of 73.38, a P/E/G ratio of 1.95 and a beta of 0.74. The stock’s fifty day moving average is $328.50 and its two-hundred day moving average is $324.56.

Penumbra (NYSE:PEN) last posted its earnings results on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The business had revenue of $374.76 million during the quarter, compared to analysts’ expectations of $370.47 million. During the same quarter in the prior year, the firm earned $0.83 EPS. Penumbra’s revenue for the quarter was up 15.6% compared to the same quarter last year. Equities analysts expect that Penumbra, Inc. will post 5.08 EPS for the current year.

Wall Street Analysts Forecast Growth

PEN has been the topic of a number of analyst reports. Citigroup reduced their price objective on Penumbra from $374.00 to $350.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th. Wall Street Zen upgraded Penumbra to a “hold” rating in a research report on Saturday, May 9th. UBS Group reiterated a “neutral” rating and set a $374.00 price objective on shares of Penumbra in a research report on Thursday, February 26th. Finally, Evercore reiterated an “outperform” rating and set a $335.00 price objective on shares of Penumbra in a research report on Thursday, May 7th. Three research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $361.33.

Penumbra Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.